Enterprise Value

2.792B

Cash

451.7M

Avg Qtr Burn

-49.34M

Short % of Float

5.87%

Insider Ownership

4.96%

Institutional Own.

70.74%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ARO-APOC3 Details
Severe hypertriglyceridemia, Familial chylomicronemia syndrome

Phase 3

Data readout

Fazirsiran (ARO-AAT) (TAK-999) Details
Severe alpha-1 antitrypsin deficiency, Liver disease

Phase 3

Update

ARO-ANG3 Details
Dyslipidemia

Phase 2b

Interim update

ARO-ANG3 Details
Dyslipidemia

Phase 2

Update

ARO-C3 (RNAi) Details
Paroxysmal nocturnal hemoglobinuria , Renal disease

Phase 1/2

Interim update

ARO-MUC5AC Details
Lung disease, Muco-Obstructive Lung Diseases

Phase 1/2

Update

ARO-MMP7 Details
Idiopathic pulmonary fibrosis

Phase 1/2

Update

ARO-RAGE Details
Muco-Obstructive Lung Diseases, Asthma, Inflammatory disease

Phase 1/2

Update

ARO-DUX4 Details
Facioscapulohumeral muscular dystrophy

Phase 1/2

Initiation

ARO-HSD Details
Liver disease, Non-alcoholic steatohepatitis

Failed

Discontinued

Failed

Discontinued